Aberdeen Group
BCRX icon

Aberdeen Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Aberdeen Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.1M Buy
5,310,871
+270,201
+5% +$2.44M 0.07% 218
2026
Q1 		$48M Buy
5,040,670
+4,127,077
+452% +$32.1M 0.08% 224
2025
Q4 		$7.13M Buy
+913,593
New +$6.6M 0.01% 661
2024
Q1 		– Sell
-504,528
Closed -$3.02M – 952
2023
Q4 		$3.02M Buy
+504,528
New +$2.92M 0.01% 742

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Aberdeen Group's BCRX Position: Q2 2026 in Review

Aberdeen Group increased its BioCryst Pharmaceuticals (BCRX) stake by 5.4% in Q2 2026, buying an estimated $2.44M and bringing the position to 5,310,871 shares worth $53.1M. The position accounts for 0.07% of the portfolio, ranked #218.

Aberdeen Group first reported a position in BCRX in Q4 2023 and has held it in 4 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Aberdeen Group held 5,310,871 shares of BioCryst Pharmaceuticals worth $53.1M as of Q2 2026.
  • Aberdeen Group bought 270,201 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $2.44M.
  • BioCryst Pharmaceuticals made up 0.07% of Aberdeen Group's portfolio in Q2 2026, its #218 holding.
  • Aberdeen Group first reported a position in BioCryst Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.